Cidara Therapeutics Total Assets 2014-2022 | CDTX

Cidara Therapeutics total assets from 2014 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Cidara Therapeutics Annual Total Assets
(Millions of US $)
2022 $48
2021 $75
2020 $60
2019 $69
2018 $79
2017 $79
2016 $107
2015 $110
2014 $24
2013 $0
Cidara Therapeutics Quarterly Total Assets
(Millions of US $)
2022-12-31 $48
2022-09-30 $67
2022-06-30 $40
2022-03-31 $55
2021-12-31 $75
2021-09-30 $51
2021-06-30 $64
2021-03-31 $54
2020-12-31 $60
2020-09-30 $64
2020-06-30 $73
2020-03-31 $84
2019-12-31 $69
2019-09-30 $82
2019-06-30 $52
2019-03-31 $64
2018-12-31 $79
2018-09-30 $93
2018-06-30 $107
2018-03-31 $70
2017-12-31 $79
2017-09-30 $67
2017-06-30 $81
2017-03-31 $93
2016-12-31 $107
2016-09-30 $82
2016-06-30 $90
2016-03-31 $99
2015-12-31 $110
2015-09-30 $117
2015-06-30 $124
2015-03-31 $61
2014-12-31 $24
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.072B $0.064B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.172B 8.84
GSK (GSK) United Kingdom $75.535B 9.47
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.564B 19.57
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.289B 0.00
Biohaven (BHVN) United States $0.959B 0.00
Emergent Biosolutions (EBS) United States $0.444B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.111B 0.00
SQZ Biotechnologies (SQZ) United States $0.019B 0.00
Gelesis Holdings (GLS) United States $0.013B 0.00